Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus (AAV) vectors are effective gene delivery vehicles mediating long-lasting transgene expression. Data from a clinical trial of AAV2-mediated hepatic transfer of the Factor IX gene (F9) into hemophilia B subjects suggests that CTL responses against AAV capsid can eliminate transduced hepatocytes and prevent long-term F9 expression. However, the capacity of hepatocytes to present AAV capsid-derived antigens has not been formally demonstrated, nor whether transduction by AAV sensitizes hepatocytes for CTL-mediated destruction. To investigate the fate of capsids after transduction, we engineered a soluble TCR for the detection of capsid-derived peptide:MHC I (pMHC) complexes. TCR multimers exhibited antigen and HLA specificity and possessed high binding affinity for cognate pMHC complexes. With this reagent, capsid pMHC complexes were detectable by confocal microscopy following AAV-mediated transduction of human hepatocytes. Although antigen presentation was modest, it was sufficient to flag transduced cells for CTL-mediated lysis in an in vitro killing assay. Destruction of hepatocytes was inhibited by soluble TCR, demonstrating a possible application for this reagent in blocking undesirable CTL responses. Together, these studies provide a mechanism for the loss of transgene expression and transient elevations in aminotransferases following AAV-mediated hepatic gene transfer in humans and a potential therapeutic intervention to abrogate these limitations imposed by the host T cell response.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additional characterization showed capsid-specific CD8+ T cells eliminate human hepatocytes after cross-presentation of capsid peptides on MHC I in vitro [89].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [89]
Citations
Cites
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544 · cited 1×
“Soluble MHC multimers were developed over a decade ago and have been used successfully to enumerate antigen-specific T cells (11).”
MethodCytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 1×
“In a phase I clinical trial the superagonist anti-CD28 monoclonal antibody TGN1412 induced a massive cytokine storm in human recipients, resulting in multiorgan failure in 6 healthy volunteers at 1/500th the dose that appeared safe in mice and nonhuman primates (44).”
BackgroundManno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 7×
“The studies above support previous observations from a human clinical trial of AAV-mediated hepatic gene transfer in which transgene expression was transient and coincided with selflimited elevations in circulating markers of hepatocyte injury (1).”
BackgroundResultInfluentialSelf-citationLIGAND RECOGNITION BY αβ T CELL RECEPTORS
Davis, M. M., Boniface, J. J., Reich, Z., Lyons, D., Hampl, J., Arden, B., & Chien, Y.-H. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.523 · Cited by 924
Limmer, A., Ohl, J., Kurts, C., Ljunggren, H.-G., Reiss, Y., Groettrup, M., Momburg, F., Arnold, B., & Knolle, P. A. (2000) · Nature Medicine · doi:10.1038/82161 · Cited by 758 · cited 1×
“In this regard, both liver sinusoidal endothelial cells (36) and hepatocytes (37) have been shown to be capable of presenting exogenous antigen, although the molecular details have yet to be completely elucidated.”
BackgroundER–phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells
Guermonprez, P., Saveanu, L., Kleijmeer, M., Davoust, J., van Endert, P., & Amigorena, S. (2003) · Nature · doi:10.1038/nature01911 · Cited by 753 · cited 1×
“If a preformed capsid engages antigen processing machinery while still within endosomes, then cross-presentation pathways are likely involved (34, 35).”
BackgroundCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 5×
“In addition, AAV2 capsid–specific CD8+ T cells were detectable following vector administration, and their frequency expanded and contracted in temporal correlation with hepatocellular injury (2).”
BackgroundMethodInfluentialSelf-citationEvidence that a Single Peptide–MHC Complex on a Target Cell Can Elicit a Cytolytic T Cell Response
Sykulev, Y., Joo, M., Vturina, I., Tsomides, T. J., & Eisen, H. N. (1996) · Immunity · doi:10.1016/s1074-7613(00)80483-5 · Cited by 703
Phagosomes are competent organelles for antigen cross-presentation
Houde, M., Bertholet, S., Gagnon, E., Brunet, S., Goyette, G., Laplante, A., Princiotta, M. F., Thibault, P., Sacks, D., & Desjardins, M. (2003) · Nature · doi:10.1038/nature01912 · Cited by 699 · cited 1×
“If a preformed capsid engages antigen processing machinery while still within endosomes, then cross-presentation pathways are likely involved (34, 35).”
BackgroundT cell killing does not require the formation of a stable mature immunological synapse
Purbhoo, M. A., Irvine, D. J., Huppa, J. B., & Davis, M. M. (2004) · Nature Immunology · doi:10.1038/ni1058 · Cited by 577 · cited 1×
“In an alternative approach, CTLs have been shown to have detectable increases in intracellular calcium after stimulation by 1 pMHC complex, inducible cytotoxic activity by 1–3 complexes, and maximal calcium flux with mature immunologic synapse formation by 8–10 complexes (42, 43).”
Background
Research works printed but not linked: 1
- Mingozzi, 2003, J. Clin. Invest., 111, 1347, 10.1172/JCI200316887 · doi:10.1172/jci200316887 · Paper page
Cited by
Items 101–196 of 196
Nienhuis, A. W., Nathwani, A. C., & Davidoff, A. M. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.018 · Cited by 27
“12,13 Systematic studies have resulted in the identification of multiple AAV serotypes.”
Weber‐Adrian, D., Kofoed, R. H., Silburt, J., Noroozian, Z., Shah, K., Burgess, A., Rideout, S., Kügler, S., Hynynen, K., & Aubert, I. (2021) · Scientific Reports · doi:10.1038/s41598-021-81046-5 · Cited by 30
Gene Therapy for Hemophilia: Progress to Date
Chapin, J. C., & Monahan, P. E. (2017) · BioDrugs · doi:10.1007/s40259-017-0255-0 · Cited by 26
“, the hepatocyte), the AAV capsid undergoes intracellular processing so that capsid epitopes are presented on the cell surface by MHC class I [117] for recognition and engagement by the T cell receptor.”
BackgroundHaemophilia gene therapy: From trailblazer to gamechanger
Evens, H., Chuah, M., & VandenDriessche, T. (2018) · Haemophilia · doi:10.1111/hae.13494 · Cited by 26
Vandamme, C., Xicluna, R., Hesnard, L., Devaux, M., Jaulin, N., Guilbaud, M., Le Duff, J., Couzinié, C., Moullier, P., Saulquin, X., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03110 · Cited by 23
“Those peptide-MHC (p-MHC) complexes serve as docking sites for recognition by memory capsid-specific CD8 T cells which then activate and expand, leading to the destruction of the transduced cells (12).”
BackgroundChai, Z., Zhang, X., Dobbins, A., Rigsbee, K. M., Wang, B., Samulski, R., & Li, C.-W. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.233 · Cited by 22
“High liver transduction from the dexamethasone treatment may raise concerns relating to the AAV capsid-specific CTL response, as described above.(28,47,48) The capsid antigen presentation in AAV target cells is dose dependent.”
BackgroundXenogeneic Liver Models for Gene Therapy
VandenDriessche, T., & Chuah, M. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.1211 · Cited by 22
“This T cell response was directed at the AAV capsid-derived antigenic peptides that were presented in association with MHC-I on the surface of the transduced human hepatocytes, possibly via ‘‘cross-presentation’’ (Pien et al. , 2009).”
The gene therapy journey for hemophilia: are we there yet?
High, K. A. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.375.3797885 · Cited by 23
Self-citationDetection of EPO gene doping in blood
Neuberger, E. W. I., Jurkiewicz, M., Moser, D., & Simon, P. D. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1347 · Cited by 23
Talla, V., Porciatti, V., Chiodo, V. A., Boye, S. L., Hauswirth, W. W., & Guy, J. R. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-14688 · Cited by 24
Hashimoto, H., Mizushima, T., Chijiwa, T., Nakamura, M., & Suemizu, H. (2017) · Virus Research · doi:10.1016/j.virusres.2017.05.017 · Cited by 21
Ling, C., Li, B., Ma, W., & Srivastava, A. (2016) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.054 · Cited by 22
Genetic manipulation of brain endothelial cells in vivo
Assmann, J. C., Körbelin, J., & Schwaninger, M. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.10.006 · Cited by 23
Chen, M., Kim, B., Jarvis, M., Fleury, S., Deng, S., Nouraein, S., Butler, S. S., Lee, S., Chambers, C., Hodges, H. C., et al. (2022) · Gene Therapy · doi:10.1038/s41434-022-00371-0 · Cited by 20
Delivery of Antigens by Viral Vectors for Vaccination
Krause, A., & Worgall, S. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.84 · Cited by 21
Stone, D., Kenkel, E. J., Loprieno, M. A., Tanaka, M., Feelixge, H. S. D. S., Kumar, A. J., Stensland, L., Obenza, W., Wangari, S., Ahrens, C. Y., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.113 · Cited by 21
“Previous studies in humans and macaques have seen transaminitis following delivery of AAV2, AAV8, or variant AAV9 vectors at doses ranging from 2 · 10(12) to 2 · 10(14) vector genomes (vg)/ kg,(20,21,26,38,81) which is thought to be caused by CTLmediated lysis of AAV-transduced hepatocytes after systemic AAV administr…”
BackgroundMHCEpitopeEnergy, a Flexible Rosetta-Based Biotherapeutic Deimmunization Platform
Yachnin, B. J., Mulligan, V. K., Khare, S. D., & Bailey‐Kellogg, C. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00056 · Cited by 20
Perinatal Gene Transfer to the Liver
McKay, T. R., Rahim, A. A., Buckley, S. M. K., Ward, N. J., Chan, J. K. Y., Howe, S. J., & Waddington, S. N. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211797247541 · Cited by 20
“AAV2 delivery to humans with severe hemophilia B resulted in expression of therapeutic factor IX concentrations for up to eight weeks [53] before an anti-capsid immune response eliminated those hepatocytes that had been infected with the AAV vector [54].”
BackgroundPreclinical models to assess the immunogenicity of AAV vectors
Ertl, H. C. J. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.11.006 · Cited by 22
Palaschak, B., Marsic, D., Herzog, R. W., Zolotukhin, S., & Markusic, D. M. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.04.004 · Cited by 19
Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models
Markusic, D. M., Nichols, T. C., Merricks, E. P., Palaschak, B., Zolotukhin, I., Marsic, D., Zolotukhin, S., Srivastava, A., & Herzog, R. W. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1200-1 · Cited by 19
Ex Vivo Gene Therapy in Organ Transplantation: Considerations and Clinical Translation
Mendiola, M., & Bowles, D. E. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.193 · Cited by 19
“45 As described above, EVMP-mediated gene delivery has the potential to administer lower doses of viral vector to organs, isolated from the recipient immune response, thus circumventing activation of a T cell-mediated immune response.”
Ortved, K. F., Wagner, B., Calcedo, R., Wilson, J. M., Schaefer, D. M. W., & Nixon, A. J. (2015) · Human Gene Therapy · doi:10.1089/hum.2014.050 · Cited by 19
“35 T-regulatory responses were not evaluated in this study, although their role in AAV-mediated transgene expression was described by Mueller and colleagues, 36 in which long-term M-type a 1 - antitrypsin (M-ATT) expression was seen in the muscle of patients despite a T cell response.”
Distinct transduction of muscle tissue in mice after systemic delivery of AAVpo1 vectors
Tulalamba, W., Weinmann, J., Pham, Q. H., Andari, J. E., VandenDriessche, T., Chuah, M., & Grimm, D. (2019) · Gene Therapy · doi:10.1038/s41434-019-0106-3 · Cited by 18
Cocaine Hydrolase Gene Therapy for Cocaine Abuse
Brimijoin, S., & Gao, Y. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.11.183 · Cited by 18
Han, J., Zhu, L., Zhang, J., Guo, L., Sun, X., Huang, C., Xu, K., Zhang, Y., Li, W., & Zhou, Q. (2022) · Cell Proliferation · doi:10.1111/cpr.13339 · Cited by 20
“Later studies have also shown that cytotoxic CD8+ T cells recognize capsid-derived epitopes via major histocompatibility complex class I (MHC class I) on the transduced cells, and partly due to high abundance of unmethylated CpG motifs in the viral genome.(28,29)”
BackgroundZhu, Z. G., Chen, W., Hao, L., Zhu, G., Lü, Y., Li, S., Wang, L., & Li, Y. (2015) · Journal Of Clinical Periodontology · doi:10.1111/jcpe.12415 · Cited by 17
“Gene transfer with AAV2 has been shown to be safe and effective in a number of disease models (Gombash et al., 2013, Xu et al., 2014, Pien et al., 2009).”
BackgroundDuan, D., & Herzog, R. W. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.067 · Cited by 24
(2025) · doi:10.1093/protein/gzaf003 · Cited by 15
rAAV expressing recombinant neutralizing antibody for the botulinum neurotoxin type A prophylaxis
Derkaev, A. A., Ryabova, E. I., Esmagambetov, I. B., Shcheblyakov, D. V., Godakova, S. A., Vinogradova, I. D., Noskov, A. N., Logunov, D. Y., Naroditsky, B. S., & Al, G. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.960937 · Cited by 17
“The choice of different rAAV– B11-Fc experimental doses was based on the data obtained by other researchers earlier when rAAV was used for the treatment of various diseases (Pien et al., 2009; Hsu and Safdar, 2011; Balazs et al., 2013; Greig et al., 2014; Hanlon et al., 2019).”
MethodCurrent and Emerging Issues in Adeno-Associated Virus Vector-Mediated Liver-Directed Gene Therapy
Piccolo, P., & Brunetti‐Pierri, N. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.179 · Cited by 17
“54,55 Although not typically performed in AAV gene therapy trials, the limited availability of liver biopsies showing in fl amma-tory in fi ltrates supports the proposed mechanism of CD8 + T-cell activation.”
Lu, H., Qu, G., Yang, X., Xu, R., & Xiao, W. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.005 · Cited by 14
“…vector targeting the liver suggested that AAV capsid proteins, from either the capsid itself or rcAAV particles, may have caused the destructive immune response/ inflammation that eventually eliminated the therapeutic gene expression (Li et al., 2009a,b; Mays and Wilson, 2009; Pien et al., 2009).”
InfluentialrAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19
Esmagambetov, I. B., Ryabova, E. I., Derkaev, A. A., Shcheblyakov, D. V., Dolzhikova, I. V., Favorskaya, I. A., Grousova, D. M., Dovgiy, M. A., Prokofiev, V. V., Gosudarev, A. I., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1129245 · Cited by 17
Hepatic AAV Gene Transfer and the Immune System: Friends or Foes?
Herzog, R. W. (2010) · Molecular Therapy · doi:10.1038/mt.2010.96 · Cited by 17
Recent Advances in Fetal Gene Therapy
Buckley, S. M. K., Rahim, A. A., Chan, J. K. Y., David, A. L., Peebles, D., Coutelle, C., & Waddington, S. N. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.17 · Cited by 14
Helper-dependent adenoviral vectors
Brunetti‐Pierri, N., & Ng, P. (2010) · Springer eBooks · doi:10.1007/978-3-0346-0165-8_13 · Cited by 14
Influence of Immune Responses in Gene/Stem Cell Therapies for Muscular Dystrophies
Farini, A., Sitzia, C., Erratico, S., Meregalli, M., & Torrente, Y. (2014) · BioMed Research International · doi:10.1155/2014/818107 · Cited by 12
“Activated CD8+ T cells can elicit indirectly the function of CD4+ T cells by secreting proinflammatory cytokines (IFN𝛾, TNF-𝛼, and IL-2) [57].”
BackgroundInfluentialProgress towards gene therapy for haemophilia B
Patel, N., Reiss, U. M., Davidoff, A. M., & Nathwani, A. C. (2014) · International Journal of Hematology · doi:10.1007/s12185-014-1523-0 · Cited by 13
“These empty particles cannot mediate FIX expression, but can serve as antigenic targets for capsidspecific cytotoxic T cells following transduction of hepatocytes [20].”
BackgroundInfluentialImmunosuppression Decreases Inflammation and Increases AAV6-hSERCA2a-Mediated SERCA2a Expression
Zhu, X., McTiernan, C. F., Rajagopalan, N., Shah, H., Fischer, D., Toyoda, Y., Letts, D. P., Bortinger, J., Gibson, G. A., Xiang, W., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.108 · Cited by 14
“…et al. , 2010); (2) some studies suggest long-term persistence of AAV-antigens after viral delivery (Jiang et al. , 2006; Stieger et al. , 2009); and (3) even low levels of viral capsid antigen:MHC complexes can target cells for recognition by peptide-specific cytotoxic T cells (Pien et al. , 2009).”
Sonogenetics in the Treatment of Chronic Diseases: A New Method for Cell Regulation
Zhu, M., Fang, Y., Sun, Y.-K., Li, S., Yu, J., Xiong, B., Wen, C., Zhou, B., Huang, B., Yin, H., et al. (2024) · Advanced Science · doi:10.1002/advs.202407373 · Cited by 14
Heckel, J., Martinez, A., Elger, C., Haindl, M., Leiß, M., Ruppert, R., Williams, C., Hubbuch, J. J., & Graf, T. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101148 · Cited by 10
“13,14 However, it was shown that non fi lled capsids can be used as a decoy for preexisting humoral immunity, depending on the patient ’ s anti-AAV antibody level.”
BackgroundKleven, M. D., Gomes, M. M., Wortham, A. M., Enns, C. A., & Kahl, C. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194728 · Cited by 9
Advances in designing Adeno-associated viral vectors for development of anti-HBV gene therapeutics
Mnyandu, N., Limani, S. W., Arbuthnot, P. B., & Maepa, M. B. (2021) · Virology Journal · doi:10.1186/s12985-021-01715-9 · Cited by 9
Helper-Dependent Adenoviral Vectors
Brunetti‐Pierri, N., & Ng, P. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800276-6.00017-6 · Cited by 10
Adeno‐associated viral vector gene therapy: Challenges for the paediatric hepatologist
Jagadisan, B., & Dhawan, A. (2024) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.12326 · Cited by 9
The HLA class I immunopeptidomes of AAV capsid proteins
Brito-Sierra, C. A., Lannan, M. B., Malherbe, L. P., & Siegel, R. W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1212136 · Cited by 7
“Among these identical peptide sequences, we identified the highly validated AAV2 epitope VPQYGYLTL (6, 19) (Table 3, Supplemental Table 2) and its AAV6/AAV9 homolog IPQYGYLTL (6, 16, 19) (Table 3, Supplemental Tables 3, 4).”
BackgroundAbdelhamid, L., & Mazor, R. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01127-5 · Cited by 7
“In parallel, T cell activation can result in CTL killing of transduced cells (36), which may result in reduced transgene expression (37) and may lead to hepatoxicity (38) and other adverse reactions (39) (Fig.”
Adenoviral Vectors for Hemophilia Gene Therapy
Brunetti‐Pierri, N. (2013) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.s1-017 · Cited by 9
“The source of immunogen has been attributed to AAV capsid peptides derived directly from the injected particles [51,53,54].”
BackgroundKuroda, M., Saitō, Y., Aso, M., & Yokote, K. (2018) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c17-00786 · Cited by 7
VandenDriessche, T. (2009) · Blood · doi:10.1182/blood-2009-07-228510 · Cited by 7
Gene Therapy in Pediatric Liver Disease
Muro, A. F., D’Antiga, L., & Mingozzi, F. (2019) · Springer eBooks · doi:10.1007/978-3-319-96400-3_44 · Cited by 7
Self-citationCai, X., Zhang, X., & Bai, H. (2020) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/ypgx4 · Cited by 6
AAV Vector-Based Gene Therapy, Progress and Current Challenges
Kuranda, K., & Mingozzi, F. (2017) · Springer eBooks · doi:10.1007/978-3-319-53457-2_5 · Cited by 5
Self-citationRecent developments in translational imaging of in vivo gene therapy outcomes
Day, I. L., Tamboline, M., Lipshutz, G. S., & Xu, S. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.049 · Cited by 5
Safety of in vivo gene therapy in children: mechanisms and management of liver injury
Jeyaraj, R., Brown, L. K., Jagadisan, B., Muntoni, F., Baruteau, J., Gupte, G. L., Breuer, J., Gissen, P., Oo, Y. H., & Dhawan, A. (2026) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(25)00380-3 · Cited by 5
(2024) · doi:10.1016/j.immuno.2024.100035 · Cited by 4
Rapti, K., Hajjar, R. J., & Weber, T. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-891-7_12 · Cited by 4
Viral vectors in neurodegenerative diseases: immune responses and therapeutic applications
Wang, Y., Mu, S., & Liu, F. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1603125 · Cited by 7
Reduced rAAV interference enhances rcAAV detection sensitivity
Yang, M., Shaheen, S., Yang, K., Gao, X., Wu, K., Zhu, X., Kang, Q., Wang, L., Hemmatzadeh, F., Zheng, Q., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101584 · Cited by 3
Current Status of Clinical Gene Therapy for Hemophilia and Globin Disorders
Winkler, R., Herath, I., Kaczmarek, R., Xiao, W., Herzog, R. W., & Severeid, P. (2026) · Journal of Blood Medicine · doi:10.2147/jbm.s576017 · Cited by 3
“39,50,51 To minimize T cell activation, therapeutic vector genomes are now depleted of immune stimulatory CpG motifs.”
Recent Advances in Designing Adeno-Associated Virus-Based Vaccines Against Viral Infections
Mnyandu, N., Jacobs, R., Arbuthnot, P. B., & Maepa, M. B. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111360 · Cited by 3
“This eliminates antigens and establishes an immunological memory [43,45,46].”
Challenges in Cardiomyopathy Gene Therapy Clinical Trial Design
Satish, T., Hong, K. N., Kaski, J. P., & Greenberg, B. H. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.08.024 · Cited by 3
Crossing the Blood-Brain Barrier with AAVs: What’s After SMA?
Chan, Y. A., & Deverman, B. E. (2022) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-030-88773-5_21 · Cited by 3
Gene Therapy for Heart Failure: Impact on Mitochondrial Dysfunction
Blagonravov, M. L., Sklifasovskaya, A. P., Karpov, R. M., Ovechkina, V. S., Andrianova, S. K., Syatkin, S. P., Belousov, V. V., & Mozhaev, A. A. (2026) · Biomedicines · doi:10.3390/biomedicines14020344 · Cited by 2
“However, a significant cytotoxic CD8+ T-cell response to the AAV capsid is predominantly observed in the liver [110], in contrast, muscle tissue demonstrates a notable resistance to the elimination of transgene-expressing cells [98,111].”
Helper-Dependent Adenoviral Vectors for Gene Therapy
Brunetti‐Pierri, N., & Ng, P. (2015) · CRC Press eBooks · doi:10.1201/b18002-5 · Cited by 2
Molecular Clinical Genetics and Gene Therapy
Flake, A. W. (2012) · Elsevier eBooks · doi:10.1016/b978-0-323-07255-7.00002-7 · Cited by 2
Evaluating Readministration of Adeno-Associated Virus for Gene Therapy
Arjomandnejad, M., & Keeler, A. M. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.29204.mar · Cited by 2
“17 Another promising approach is utilizing immunoglobulin-degrading enzymes (IdeS or IdeZ).”
Immune System Obstacles to In vivo Gene Transfer with Adeno-Associated Virus Vectors
Büning, H., & Mingozzi, F. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800563-7.00004-x · Cited by 1
Self-citationGene Therapy and Cell Therapy: Bioanalytical Challenges and Practical Solutions
Jani, D., Boyanapalli, R., & Cao, L. (2022) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-030-97193-9_5 · Cited by 1
Upregulation of CD8+ regulatory T cells following liver-directed AAV gene therapy
Gaddie, C. D., Senior, K. G., Chan, C. T., Hoffman, B. E., & Keeler, G. D. (2024) · Cellular Immunology · doi:10.1016/j.cellimm.2024.104806 · Cited by 2
Immunogenicity of AAV Gene Therapy Products
Jawa, V., & Wu, B. (2024) · Wiley eBooks · doi:10.1002/9781119852810.ch5 · Cited by 1
The State of the Art and Future of Gene Medicines
Jacobs, F., Gordts, S. C., & Geest, B. D. (2013) · Wiley eBooks · doi:10.1002/9780470571224.pse515 · Cited by 1
Viral vector-mediated RNA interference in the retina
Georgiadis, A. (2010) · UCL Discovery (University College London)
Soluble T‐Cell Antigen Receptors
Rhode, P. R. (2013) · Wiley eBooks · doi:10.1002/9781118354599.ch31
Gene Therapy Trials in Hemophilia A and B
High, K. A. (2014) · Wiley eBooks · doi:10.1002/9781118398258.ch41
Self-citationAdenovirus-based gene therapy approaches for hemophilia B
Zhang, W. (2012) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.14566
[Cellular immunotoxicity of rAAV gene medicine and possible solutions].
Diao, Y., Qizhao, W., Xiao, W., & Xu, R. (2010) · PubMed
Intracellular fate of AAV particles in human Dendritic Cell and impact on Gene Transfer
Rossi, A. (2016) · theses.fr (ABES) · doi:10.70675/4518d4eazdbd8z4f46z96e2zf87942913c70
“It is closely linked to the rAAV doses and it was also observed for other serotypes [177], [187].”
BackgroundGene Therapy Trials in Hemophilia A and B
High, K. A., & Wright, J. F. (2010) · Wiley eBooks · doi:10.1002/9781444318555.ch36
Self-citationNicolson, S. C. (2014) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/gbv4-z740
CHITOSAN-MEDIATED ORAL GENE THERAPY FOR HEMOPHILIA TREATMENT AND PROPHYLACTIC TOLERANCE
Dhadwar, S. (2011) · MacSphere (McMaster University) · doi:10.71548/13013
Mingozzi, F., & Junge, N. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-63671-1.00033-1
Self-citationHelper-Dependent Adenoviral Vectors
Ng, P. (2022) · CRC Press eBooks · doi:10.1201/9781003247432-15
Gupta, N., Koduru, T. S., Sharadha, M., Chakraborty, S., Balamuralidhara, V., & Alexander, A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99616-7.00008-6
MMEJ-mediated IDLV knock-in via CRISPR/Cas9 in human hematopoietic stem/progenitor cells.
Sakkal, A. (2023) · theses.fr (ABES) · doi:10.70675/678681caza0bdz47cbz8307zddd952dfde91
Balasubramanian, A., Prachař, M., Klaproth, B., Copeland, V., Justesen, S. F. L., Wen, Y., Siegel, R. W., & Malherbe, L. P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1641289 · Cited by 2
Exploring potential analgesic targets and tools for chronic pain treatment
Haroun, R. (2023) · UCL Discovery (University College London)
Characterisation of AAV capsid-specific CD8+ T cell responses in human subjects
Vandamme, C. (2016) · theses.fr (ABES) · doi:10.70675/371e4bbfze69az417bz960azf9db02287546
Characterization of rAAV vectors packaging in baculovirusinfected insect cells
Penaud‐Budloo, M. (2018) · theses.fr (ABES) · doi:10.70675/c5cff6daz8fe4z430cz80e6z97a11cc59c8e
Etude de la réponse immunitaire virale préexistante anti-AAV chez l'homme
Xicluna, R. (2019) · theses.fr (ABES) · doi:10.70675/d2f47d7cz4f46z448cz85afz657c9516c86f · Cited by 1
Creisméas, A. (2022) · theses.fr (ABES) · doi:10.70675/7e452f5az22a1z433az83a8z1fe23089846a
Hu, S., Chen, Y., Wu, C., Reuter, W. H., Deng, J., Jia, N., Walsh, N., Bastille, A., Edwards, T. M. E., Hebben, M., et al. (2026) · Microorganisms · doi:10.3390/microorganisms14081857
“This concern is supported by clinical observations from hemophilia B gene therapy studies, in which AAV capsid-specific CD8+ T-cells responses were associated with loss of transgene expression [38,39] even though the immune response was not directly attributed to rcAAV.”
Metadata
- Authors
- Pien, G. C., Basner-Tschakarjan, E., Hui, D. J., Mentlik, A. N., Finn, J. D., Hasbrouck, N. C., Zhou, S., Murphy, S. L., Maus, M. V., Mingozzi, F., Orange, J. S., & High, K. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Corresponding author
- High, Katherine A.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2009-06-01
- Volume
- 119
- Issue
- 6
- Pages
- 1688-1695
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2689109
- OpenAlex
- W2131862356
- Cited by
- 192
- References
- 51
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 13 · 2023: 10 · 2022: 13 · 2021: 10 · 2020: 12 · 2019: 9 · 2018: 10 · 2017: 15 · 2016: 8 · 2015: 13 · 2014: 13 · 2013: 13 · 2012: 11
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Children's Hospital of Philadelphia
- National Institutes of Health (AI067946)
- National Heart, Lung, and Blood Institute (P01HL078810, T32HL007439, T32HL007150)
- National Institute of Allergy and Infectious Diseases (R01 AI067946S1, R01AI067946)
- National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus, antigen presentation, hepatocytes, cytotoxic T lymphocytes, T cell-mediated lysis, peptide-MHC class I complexes, AAV2, hemophilia B, hepatic gene transfer, aminotransferase elevation, host immune response
- MeSH terms
- Dependovirus, Cell Line, Cytotoxicity, Immunologic, Genetic Vectors, Histocompatibility Antigens, Humans, Receptors, Antigen, T-Cell, Solubility, Substrate Specificity, T-Lymphocytes, Cytotoxic, Antigen Presentation, Hepatocytes, Capsid Proteins, Protein Multimerization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.